Neurocrine Biosciences Financial Statements (NBIX)
|
|
|
|
Report date
|
|
|
31.10.2023 |
09.02.2024 |
01.05.2024 |
01.08.2024 |
30.10.2024 |
|
30.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
498.8 |
515.2 |
515.3 |
590.2 |
622.1 |
|
2 243 |
|
Operating Income, bln rub |
|
|
141.2 |
150.3 |
105.3 |
147.9 |
183.8 |
|
587.3 |
|
EBITDA, bln rub |
? |
|
146.7 |
156.0 |
111.5 |
155.2 |
196.8 |
|
619.5 |
|
Net profit, bln rub |
? |
|
83.1 |
147.7 |
43.4 |
65.0 |
129.8 |
|
385.9 |
|
|
OCF, bln rub |
? |
|
212.0 |
123.5 |
130.3 |
64.6 |
158.0 |
|
476.4 |
|
CAPEX, bln rub |
? |
|
7.60 |
5.40 |
11.2 |
11.6 |
8.10 |
|
36.3 |
|
FCF, bln rub |
? |
|
204.4 |
118.1 |
119.1 |
53.0 |
149.9 |
|
440.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
346.4 |
356.4 |
397.2 |
426.7 |
430.3 |
|
1 611 |
|
Cost of production, bln rub |
|
|
11.2 |
8.50 |
12.8 |
15.6 |
8.00 |
|
44.9 |
|
R&D, bln rub |
|
|
142.2 |
137.5 |
154.1 |
184.7 |
195.0 |
|
671.3 |
|
Interest expenses, bln rub |
|
|
1.10 |
1.10 |
1.10 |
0.000 |
0.000 |
|
2.20 |
|
|
Assets, bln rub |
|
|
2 848 |
3 251 |
3 472 |
3 305 |
3 535 |
|
3 535 |
|
Net Assets, bln rub |
? |
|
2 002 |
2 232 |
2 386 |
2 509 |
2 719 |
|
2 719 |
|
Debt, bln rub |
|
|
255.8 |
428.4 |
546.9 |
291.6 |
251.4 |
|
251.4 |
|
Cash, bln rub |
|
|
1 095 |
1 032 |
1 211 |
1 039 |
1 228 |
|
1 228 |
|
Net debt, bln rub |
|
|
-839.3 |
-603.2 |
-663.7 |
-747.3 |
-976.6 |
|
-976.6 |
|
|
Ordinary share price, rub |
|
|
112.5 |
131.8 |
137.9 |
137.7 |
115.2 |
|
113.4 |
|
Number of ordinary shares, mln |
|
|
97.9 |
98.4 |
99.8 |
100.8 |
101.1 |
|
101.1 |
|
|
Market cap, bln rub |
|
|
11 014 |
12 965 |
13 764 |
13 877 |
11 649 |
|
11 467 |
|
EV, bln rub |
? |
|
10 174 |
12 362 |
13 101 |
13 130 |
10 672 |
|
10 490 |
|
Book value, bln rub |
|
|
1 967 |
2 191 |
2 352 |
2 470 |
2 684 |
|
2 684 |
|
|
EPS, rub |
? |
|
0.85 |
1.50 |
0.43 |
0.64 |
1.28 |
|
3.82 |
|
FCF/share, rub |
|
|
2.09 |
1.20 |
1.19 |
0.53 |
1.48 |
|
4.35 |
|
BV/share, rub |
|
|
20.1 |
22.3 |
23.6 |
24.5 |
26.6 |
|
26.6 |
|
|
EBITDA margin, % |
? |
|
29.4% |
30.3% |
21.6% |
26.3% |
31.6% |
|
27.6% |
|
Net margin, % |
? |
|
16.7% |
28.7% |
8.42% |
11.0% |
20.9% |
|
17.2% |
|
FCF yield, % |
? |
|
3.49% |
2.79% |
4.46% |
3.56% |
3.78% |
|
3.84% |
|
ROE, % |
? |
|
9.54% |
11.2% |
15.5% |
13.5% |
14.2% |
|
14.2% |
|
ROA, % |
? |
|
6.71% |
7.68% |
10.6% |
10.3% |
10.9% |
|
10.9% |
|
|
P/E |
? |
|
57.7 |
51.9 |
37.2 |
40.9 |
30.2 |
|
29.7 |
|
P/FCF |
|
|
28.6 |
35.9 |
22.4 |
28.1 |
26.5 |
|
26.1 |
|
P/S |
? |
|
6.17 |
6.87 |
6.94 |
6.55 |
5.19 |
|
5.11 |
|
P/BV |
? |
|
5.60 |
5.92 |
5.85 |
5.62 |
4.34 |
|
4.27 |
|
EV/EBITDA |
? |
|
28.8 |
30.4 |
26.9 |
23.1 |
17.2 |
|
16.9 |
|
Debt/EBITDA |
|
|
-2.37 |
-1.49 |
-1.36 |
-1.31 |
-1.58 |
|
-1.58 |
|
|
R&D/CAPEX, % |
|
|
1 871% |
2 546% |
1 376% |
1 592% |
2 407% |
|
1 849% |
|
|
CAPEX/Revenue, % |
|
|
1.52% |
1.05% |
2.17% |
1.97% |
1.30% |
|
1.62% |
|
| Neurocrine Biosciences shareholders |
